Purpose: The correlation between glutamine metabolism and oncogene expression in cancers has lead to a renewed interest in the role of glutamine in cancer cell survival. Hyperpolarized [5-13 C]glutamine is evaluated as a potential biomarker for non-invasive metabolic measurements of drug response in prostate cancer cells.
Introduction
Prostate cancer is the second most common cause of cancer-related death among men in developed countries, second only to lung cancer (1) . Clinical management of prostate cancer, however, remains difficult due to the biological diversity of prostate cancers. This diversity necessitates highly varied treatment approaches, ranging from active surveillance to radiation therapy and surgical removal (2, 3) , often with adverse side effects (4) . Prostate cancer cells are only modestly responsive to the cytotoxic effects of currently available chemotherapeutic agents. Increased concentrations of these cytotoxic drugs fail to improve the response to clinical treatments and can lead to resistance to apoptosis in prostate cancer cells (5) .
Toxicity to normal cells is an important issue in selection of therapies and one possible strategy evaluates natural compounds that display cancer-specific cytotoxicity (6) . Resveratrol and sulforaphane are two examples of natural compounds that have attracted attention for their selective toxicity to cancer cells and for their ability to sensitize cancer cells to other therapies (7, 8) . Both Resveratrol and sulforaphane have been shown to inhibit growth and induce apoptosis in tumor cells as well as in tumor animal models (9) (10) (11) (12) .
Sulforaphane is in clinical trial phase II treating patients with recurrent prostate cancer (13) . While resveratrol has not yet been in clinical trials, phamacokinetic studies in humans have been performed paving the road for testing its anti-carcinogenic effects in humans (14) .
Metabolic hallmarks of cancer cells may lead to the identification of biomarkers needed for the evaluation and development of prostate cancer therapies. In addition to increased glycolysis, cancer cells often show increased lipogenesis and glutamine metabolism (15) . Catabolism of glutamine (glutaminolysis) takes place in all proliferating cells, but certain cancer cells exhibit a particular glutaminolytic phenotype that makes them highly dependent on glutamine for energy production 16). Cell proliferation and metabolism are tightly linked cellular processes. For some cancer cells, activation of the phosphoinositide 3-kinase (PI3K) signalling pathway is instrumental in causing increased levels of glucose uptake and leading to a significant up regulation of cellular glucose metabolism. In other cancer cells, the same signalling pathway leads to an inefficient glutamine metabolism rather than an excess glucose metabolism (17) . The latter types of cancer cells cannot survive, when there is not enough extra glutamine and are therefore said to be "addicted" to glutamine (17) . Both resveratrol and sulphoraphane have been shown to act via the PI3K signalling pathway (12, 13, 18) . PI3K occupies a central role in several cellular processes critical for cancer progression, including metabolism, growth, survival, and motility. Among other targets PI3K regulates mTORC1, which depends on glutamine for maximal activation (17) and also the cytotoxic function of resveratrol has been correlated to the presence of glutamine during cell culturing (6) . One hypothesis of this paper is thus that cellular glutaminolysis may be a biomarker for drug treatment with resveratrol and sulphoraphane.
Due to the biological diversity of prostate cancer and the lack of non-invasive clinical tools that can track tumor progression and effect of therapy, repeated invasive examinations of the patient is currently inevitable. Technologies for non-invasive, reliable and accurate measurements of tumor progression and antitumor effects would provide a significant advance in prostate cancer treatment. To this end, a recent technological improvement in magnetic resonance (MR), hyperpolarized 13 C-MR (19) , has radically increased the sensitivity of MR and in consequence allowed real time metabolism of 13 C-labeled substrates and their metabolites to be monitored in vivo (20) . In particular, this new technology has proven promising in the diagnosis of cancer (21) . Recently, hyperpolarized [1-13 C]pyruvate has been used as a biomarker for the diagnosis of prostate cancer in a clinical trial (22) . Although the necessary imaging technologies are available, the development of treatment strategies for prostate cancer is challenged by the lack of relevant biomarkers predictive of treatment efficacy and useful for therapy tracking (23) .
Development of biomarkers that can predict response to treatments will allow improving the efficiency of therapies or help avoid unnecessary treatments, while facilitating the evaluation of potential novel breakthrough therapies.
In the current study, we evaluate noninvasive observations of glutamine metabolism as a biomarker for the treatment of prostate cancer cells. Hyperpolarized 13 C NMR measurements were used to probe the metabolic conversion of hyperpolarized [5] [6] [7] [8] [9] [10] [11] [12] [13] C]glutamine to [5-13 C] glutamate in aggressive living prostate cancer cell lines (DU145 and PC3). Noninvasive tracking of glutaminolysis shows differences in the glutamine metabolism between DU145 and PC3 cells. In agreement with the high glutaminolytic activity, both cell lines only proliferate in the presence of glutamine in the medium, thus showing that glutamine metabolism is a significant substrate for both DU145 and PC3 cells. Glutaminolysis was ~4fold higher in DU145 cells, as validated by disruptive assays. The different glutaminolytic activity of both prostate cancer cell lines was further tracked upon exposure to two natural anticancer agents, resveratrol and sulforaphane.
Treatment with both drugs was more effective in the more glutaminolytic cell line DU145. Thus, noninvasive observations of glutamine metabolism are prospective biomarkers for cell line specific differences in glutamine metabolism and response to therapy.
Methods

Cell culture and treatments
DU145 and PC3 cells (America Tissue Culture Collection) were initially cultured in RPMI 1640 medium with 10% FBS, 100 units/ml penicillin, 100 µg/ml streptomycin, 2 g/L glucose, and 0.3 g/L L-glutamine (Sigma-Aldrich, St. Louis, MO, USA) at 37°C in a 5% CO 2 atmosphere. For cell experiments, DMEM low glucose medium (with or without glutamine) was supplemented with 10% FBS, 100 units/ml penicillin, 100 µg/ml streptomycin and 2 g/L sodium bicarbonate. The glucose concentration in DMEM low glucose media was increased up to 2 g/L glucose by adding the proper volume of D-(+)-Glucose solution of 100 g/L (Sigma-Aldrich). For cell counting experiments, cells were plated in 24 multi well plates at cell densities of 1.5x10 4 /well and 3x10 4 /well for DU145 and PC3 cells, respectively. For MTT, Nucleosoma and ATP assays, cells were plated in 96 multi well plates at densities of 7.5x10 3 /well and 12x10 3 /well for DU145 and PC3, respectively. For assays of glutamine metabolism, cells were grown in T75 flasks prepared by seeding 2x10 6 cells.
Cell treatment
Resveratrol and sulforaphane were dissolved in DMSO (Sigma-Aldrich) to obtain 100 mM and 80 mM stock solutions, respectively. Cells were plated as described above in full growth media (DMEM 2 g/L glucose, 2 mM glutamine). Following 24 h attachment, the medium was discarded and serial dilutions of the two drugs prepared in growth medium were added to cells at concentrations of 25, 50, 100, 200, 300, 400 µM of resveratrol and 5, 10, 20, 40 µM of sulforaphane. Cells cultured in medium containing 0.05 % (for sulforaphane experiments) or 0.4% DMSO (for resveratrol experiments) served as control groups.
Cell counting
Once harvested by trypsination, cells were pelleted and resuspended in an appropriate volume of PBS, then diluted 1:2 with trypan blue (Sigma-Aldrich) and counted with a hemocytometer.
ATP assay
CellTiter-Glo assay was purchased from Promega (Madison, WI, USA). Measurements were made according to the manufacturer's instructions. Briefly, plates containing 25x10 3 cells in 100 µL per well were removed from the incubator and allowed to equilibrate at room temperature for 20 minutes. An equal volume of CellTiter-Glo reagent was added directly to the wells. Plates were incubated at room temperature for 30 minutes on a shaker and luminescence was measured on a microplate reader (PerkinElmer, Waltham, MA, USA).
MTT assay
The MTT assay measures the cellular capacity to reduce 3-(4,5-dimethylthiazol-2-yl)diphenyltetrazolium bromide (Sigma-Aldrich) to blue formazan products by various oxidoreductase enzymes (24, 25) . Cells were grown in 96 well plates and after removing the supernatant, 100 µL of MTT solution (0.5 mg/mL in growth media) were added to each well. After incubation for 4 h, the resultant formazan crystals were dissolved in isopropanol (100 µL) and the absorbance intensity measured by a microplate reader at 570 nm. All experiments were performed in quadruplicate, and the MTT conversion (%) was expressed as a percentage relative to the control cells.
Nucleosome ELISA
Nucleosome Cell Death ELISA kit was acquired by Roche Applied Sciences (Germany) and used according to the instructions. Cells were grown as described above in 96 multiwell plates. After 24 h of resveratrol or sulforaphane treatments, cells were lysed with the lysis buffer supplied in the kit. Lysed cells were pelleted with a 200 g centrifugation for 10 minutes. 20 µL of supernatants were incubated in ELISA wells with 80 µL immunoreagent per well. ELISA assays were quantified at a detection wavelength of 405 nm. The enrichment of mono-and oligonucleosomes released into the cytoplasm of cell lysates was detected by biotinylated anti-histone-and peroxidase-coupled anti-DNA-antibodies and was calculated as follows, enrichment factor = absorbance of sample cells/absorbance of control cells. Both sample and control values were first corrected by subtracting the blank absorbance. Enrichment factor was used as a parameter of apoptosis (26) and is given as the mean ± SD of three independent experiments performed in triplicate.
Metabolic conversion of glutamine with RP-HPLC assay
Cells were grown in T75 flasks, harvested and assessed for viability by trypan blue exclusion. For lyzed cells, the harvested cells were submitted to three rounds of freeze-thawing at -80 °C before continuing with the assay. After centrifugation, cells were suspended by adding 225 µL 0.1 M NaH 2 PO 4 pH 7.5, 15 µL 100 mM Norvaline (internal concentration reference) and 60 µL 100 mM Glutamine (or 60 µL H 2 O in blank samples). Samples containing 0.5 million cells were incubated for 30 minutes at 37°C, then 150 µL 6% perchloric acid were added to stop the reaction and samples were put on ice for 15 min. Finally, 14 µL saturated K 2 CO 3 were added to re-equilibrate pH and samples were pelleted at 15000 g for 15 min at 4°C. Supernatants were filtered with 0.2 µm PVDF syringe filter and analysed by reverse-phase HPLC as described (27) . No de-amidation of glutamine is occurring using this mild protein denaturing procedure allowing the determination of glutamate concentrations. Three replicates for blanks and samples were prepared for each condition.
In vitro hyperpolarized 13 C-NMR polarization medium was prepared as described (28) . In brief, Ox063 radical (Albeda Research, Denmark ) and the gadolinium complex Gadoteridol (Bracco Imaging Spa, Italy) were dissolved to 35 mM and 4 mM, respectively, in anhydrous DMSO. Cesium hydroxide monohydrate (42.0 mg, 0.25 mmol) and 
Kinetic fitting
The data from the data sets containing the signals from glutamine and glutamate were first corrected for the effect of pulsing by dividing the data sets with cos(a) n where a is the flip angle (20°) and n is the pulse ordinal number. The corrected data were then fitted to the following two differential equations: 1) dS/dt = -k*S(t) -1/T1 S *S(t) 2) dP/dt = k*S(t) -1/T1 P *P(t)
Here, S denotes the signal from substrate glutamine, T1 S denoted the T 1 of glutamine, P denotes the signal from glutamate and T1 P denotes the T 1 of glutamate. The T 1 of glutamine was determined from the decay of the substrate signal (20 ± 2 s). The T 1 of glutamate was fitted to 24 ± 2 s. All fitted curves had a coefficient of determination R 2 above 0.91.
Data Analysis
Each experiment was repeated at least in triplicate and means ± SD for each value were calculated. Statistical analysis of the results was performed using the Student's t-test and one-way ANOVA, followed by Dunnett's multiple comparison test. Significant differences are indicated with "*" (P<0.05) in all figures. All the statistical analyses were performed using the statistical package GraphPad Prism. Spectral analysis was performed using the software MNova (Mestrelab Research, Santiago de Compostela, Spain).
Results
Glutamine addiction of prostate cancer cells PC3 and DU145 are widely used aggressive human prostate cancer cell lines derived from different origin.
Both cell lines have been shown to exhibit a strong dependence on glutamine for proliferation (29, 30) . This dependence may be connected to a glutaminolytic phenotype of the cell type. Cell growth characteristics were evaluated for PC3 and DU145 cell lines to compare their dependence on glutamine for growth (degree of glutamine addiction). Figure 1 Glutamine depletion is clearly able to introduce proliferation arrest in PC3 and DU145 cells, thus underlining the importance of this metabolic pathway for both cell types to propagate.
In order to noninvasively probe glutamine metabolism in real time with hyperpolarized [5- 13 C]glutamine in prostate cancer cells, a protocol was adapted that we developed previously for liver cancer cells (28) . 
Glutamine addiction correlates to glutamine metabolism in prostate cancer cells
The proliferative dependency of aggressive prostate cancer cells on glutamine availability supposedly correlates to activated oncogenes that influence glutamine catabolism (29) . The first metabolic step in glutamine catabolism is its conversion to glutamate in a reaction catalyzed by the enzyme glutaminase.
Glutamate forms from the hyperpolarized [5-13 C]glutamine probe by two catalysed steps, the cellular uptake and the glutaminase catalysed reaction. It was therefore evaluated, if hyperpolarized [5-13 C]glutamine metabolism is a possible biomarker for the glutamine dependence in prostate cancer cells. The formation of the metabolic product [5-13 C] glutamate was compared between the two prostate cancer cell types and an evaluation of the area under the curve (AUC) is shown in Figure 2D . The AUC was 37.3 ± 4.8 a.u. in DU145 cells whereas it was 9.0 ± 1.0 a.u. or approx. 4 times lower in PC3 cells. The kinetic profile is similar for the DU145 and the PC3 cells, although the latter show less product formation ( Figure 2C) . The decay over time of the hyperpolarized substrate ([5-13 C]glutamine) is identical in experiments performed with the two cell types, because the decay is dominated by relaxation rather than metabolism.
The hyperpolarization data indicating different glutamine metabolism in DU145 and PC3 cells were validated by conventional biochemical methods. To mimic the hyperpolarization protocol, glutamine was fed to whole cells (5x10 5 ) enabling a quantification of combined glutamine uptake and metabolism to glutamate.
The quantification was made with RP-HPLC after disrupting the cells with perchloric acid. Production of glutamate from glutamine was determined as 30±2 and 11±4 mU/million cells, in DU145 and PC3, respectively ( Figure 2E ). In consequence, both the non-invasive hyperpolarized NMR assay and the disruptive assay show a 3-4-fold larger metabolism of glutamine to glutamate in DU145 cells, which are more addicted to glutamine than PC3 cells. The measured glutamine to glutamate conversion was stable under the chosen growth conditions in both cell types when measured at 48 and 96 hours.
Resveratrol and sulforaphane treatment in PC3 and DU145
DU145 and PC3 cells were exposed to increasing concentrations of resveratrol and sulforaphane to determine, if the degree of glutamine addiction is reflected in the response to drug treatment. The effect of treatment was measured in both cell types as a decrease in cell proliferation, a decrease in MTT conversion and as an induction of apoptosis (Figures 3 and 4 ). Dose response curves were performed to identify the appropriate drug concentration to induce apoptosis. DU145 was sensitive to resveratrol treatment, with significant apoptosis achieved at 50 µM (p<0.05), and a maximum of 3.5 ± 0.51-fold increase in nucleosome release into the cytoplasm obtained at 200 µM. PC3 cells were less responsive to resveratrol-induced apoptosis showing significant apoptosis with 1.8 ± 0.86-fold increase in nucleosome release into the cytoplasm, only at the highest tested concentrations (300 and 400 µM; see Figure 3F ). When DU145 cell were treated with resveratrol at high concentration (400 µM, Figure 3E ) this resulted in a decrease of apoptotic enrichment factor. This effect may be due apoptotic cells progressed into late apoptotic cells (secondary necrotic cells). In this state the cell membrane becomes more permeable, resulting in the leakage of intracellular molecules such as nucleosomes release into the cytoplasm (31) .
Alternatively high concentration of an apoptosis-inducing stimulus could induce necrosis rather than apoptosis (32) .
Antiproliferative action of resveratrol in DU145 cells resulted in a 50% reduction (IC 50 ) at 100 µM. In PC3 cells, no IC 50 could be determined with reasonable drug concentrations (33) . The MTT conversion was significantly decreased to 80.82 
Discussion
The glutaminolytic phenotype shared by many tumor cell types has been associated with a cellular addiction to glutamine for the maintenance of cell viability (34) . Such glutamine addiction and a glutaminolytic phenotype have been reported for the human prostate carcinoma cell types, PC3 and DU145 (29, 30) . Our results confirmed that both cell types are highly dependent on glutamine for proliferation and showed the more aggressive prostate cancer cell type, DU145, to be more strongly dependent on glutamine for proliferation. While examples have been reported for cells with dramatically changed viability upon glutamine withdrawal (34) , the prostate cancer cell types DU145 and PC3 are able to survive in glutamine deficient medium. Glutamine deprivation instead resulted in proliferation arrest and in a growth correlated decrease in MTT conversion in both prostate cancer cell types. The MTT conversion was almost halved in DU145 cells after 24 h in glutamine depleted medium ( Figure 1C ), while it was not significantly changed in the PC3 cells at this time point ( Figure 1D ), suggesting that the DU145 cells are more glutamine dependent than PC3 cells. That DU145 cells are more addicted to glutamine than PC3 cells is further supported by a time dependent increase in PC3 cell viability for cells grown in glutamine deficient medium ( Figure 1D ). It seems that PC3 in contrast to DU145 cells pick up over time and adapt to the glutamine free growth condition.
The higher sensitivity of DU145 cells to glutamine withdrawal was correlated to a significantly higher degree of glutaminolysis in DU145 compared to the PC3 cells, as measured by glutamine metabolism to glutamate. The metabolic conversion of hyperpolarized [5] [6] [7] [8] [9] [10] [11] [12] [13] The glutamine metabolism is in both assays measured as a result of a combination of an active cellular uptake of glutamine and as a result of glutaminase activity. A situation where the uptake of glutamine is rate limiting and different in the two cell types could explain why the reported rates obtained with the two assays (hyperpolarized assay during 1.5 minute and conventional biochemical assay during 30 minutes) differs. In support of an uptake rate limitation in prostate cell glutaminolysis a three times increased glutamate production was measured in disrupted DU145 cells (1516 amoles/s/cell) and a two times increase in PC3 cells (360 amoles/s/cell). In general, the metabolic conversion of glutamine is high in both prostate cancer cell types. The conversion rate measured in PC3 cells is comparable to the rate recently reported for the glycolysis in PC3 cells (35) . This high rate of glutamine metabolism in prostate cancer cells could be the result of an increased cellular glutamine transport, as reported for malignant hepatoma cells (36, 37) and a consequence of higher glutaminase expression (29)
We exposed DU145 and PC3 cells to two well-established natural systemic drugs, resveratrol and sulforaphane, that are suggested to act on glutamine dependent cellular regulators. Metabolic response to treatment was measured for drug doses matched with maximum apoptotic effect and cellular proliferation arrest to 50%. At these drug concentrations, glutamine metabolism was approximately half of that in the Resveratrol treatment did not yield effects on apoptosis and cell proliferation in PC3 cells, while a significant decrease in glutamine metabolism by 39.6 ± 2.2% was measured in PC3 cells treated with 200 µM resveratrol. The decrease in glutamine metabolism could be correlated to a decrease in mitochondrial activity. Glutamine metabolism thus could provide an early biomarker of cellular response to drug treatment that is detectable before effects upon cell proliferation and cell death can be detected.
Our interest in this study has been to evaluate hyperpolarized [5-13 C]glutamine metabolism to hyperpolarized [5-13 C]glutamate as a possible predictive biomarker for the efficacy of prostate cancer therapy. The detection of glutamine metabolism in prostate cancer with hyperpolarized [5-13 C]glutamine was previously unsuccessful both in animals and in cells (38, 39) . We show here that the use of an improved protocol shown to work in a rat liver cancer model (28) (23) . This study shows that real time, non-invasive metabolism of hyperpolarized [5-13 C]glutamine meets these demands as the metabolism of a hyperpolarized [5-13 C]glutamine probe (i) is particularly prominent in highly glutaminolytic prostate cancer cell types, (ii) correlates to drug treatment efficacy and (iii) can be quantified in highly glutaminolytic isolated cells.
Metabolic reprogramming renders cancer cells highly dependent on specific metabolic enzymes or processes. As a predictive biomarker, glutamine metabolism offers great promise due to its central role in cancer metabolism. In consequence glutamine metabolism has previously been suggested as biomarker in tumors that fail to show high aerobic glycolysis (40) . Due to the excellent resolution of magnetic resonance spectroscopy, metabolism to glutamate can be probed by hyperpolarized NMR methods.
The noninvasive measurement of glutamine metabolism and its sensitivity to drug treatment, detected herein with hyperpolarized [5-13 C]glutamine in living prostate cancer cells, therefore potentially provides additional diagnostic and prognostic information for drug evaluation and treatment strategies in cancer. 
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